Here's some reasons to be hopeful that the early-stage life science sector is on the upswing. (though i am skeptical that the e-health ventures will deliver (in general.) investors are bringing dot-com growth expectations to regulated markets where behavior doesn't change fast. (And i'm speaking of consumer, practitioner, and payor behavior.)